Skip to main content

Table 1 Study patients’ characteristics

From: Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer

   All patients ΔNACT ΔNACT p-value
<224 pg/ml >224 pg/ml
(n = 66) (n = 48) (n = 18)
   n (%) n (%) n (%)  
Median age (range), years 59 (30–73) 57 (30–72) 61 (50–73) 0.0281
Gender Male 38 (58) 28 (58) 10 (56) 0.842
  Female 28 (42) 20 (42) 8 (44)  
TN stage T2–3 45 (68) 31 (65) 14 (78) 0.312
  T4 21 (32) 17 (35) 4 (22)  
  N0–1 16 (24) 10 (21) 6 (33) 0.353
  N2 49 (75) 37 (77) 12 (67)  
  ND 1 1 0  
Baseline CEA level ≤ULN 38 (58) 25 (52) 13 (72) 0.142
  >ULN 28 (42) 23 (48) 5 (28)  
Baseline haemoglobin level ≥LLN 54 (82) 39 (81) 15 (83) 13
  <LLN 12 (18) 9 (19) 3 (17)  
ypTN stage ypT0–2 37 (56) 22 (46) 15 (83) 0.0082
  ypT3–4 28 (42) 25 (52) 3 (17)  
  ND 1 1 0  
  ypN0 46 (70) 29 (60) 17 (94) 0.0092
ypN ypN1–2 19 (29) 18 (38) 1 (6)  
  ND 1 1 0  
TRG score TRG1–2 44 (67) 30 (63) 14 (78) 0.282
  TRG3–5 21 (32) 17 (35) 4 (22)  
  ND 1 1 0  
  1. The population of 66 study patients with paired serum sample measurements of carbonic anhydrase IX following neoadjuvant induction chemotherapy versus baseline (a variable termed ΔNACT) was divided into two groups above and below an estimated optimum cut-off ΔNACT value of 224 pg/ml. Distribution of parameters between the two groups was compared using 1: Mann-Whitney U-test, 2: Pearson’s chi-square test or 3: Fisher’s exact test
  2. ND not determined (omitted from analysis), CEA carcinoembryonic antigen, ULN upper limit of normal, LLN lower limit of normal, TRG tumour regression grade